Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen

Tessa Bystrup Boyles, Inge Marie Svane, Lars Bastholt, Henrik Schmidt

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstract

Melanoma is an aggressive form of skin cancer which is the cause of a great number of skin cancer-related deaths worldwide and about 300 deaths in Denmark. After several years of failure of treatment of metastatic melanoma, the development of BRAF- and later MEK inhibitors was considered revolutionary. Treatment with BRAF inhibitors alone and especially in combination with a MEK inhibitor improves outcome for patients with BRAF V600-mutated metastatic melanoma. However, even when treated with the combination of the inhibitors, many patients develop acquired resistance within a year.

Bidragets oversatte titelTreatment of BRAF-mutated metastatic melanoma
OriginalsprogDansk
ArtikelnummerV02160126
TidsskriftUgeskrift for Laeger
Vol/bind178
Antal sider4
ISSN0041-5782
StatusUdgivet - 2016

Citationsformater